These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 15528944)

  • 1. Intravenous vitamin D therapy reduces PTH-(1-84)/large C fragments ratio in chronic hemodialysis patients.
    Kihara T; Ichikawa H; Morimoto H; Yano A; Akagi S; Nakao K; Kohmoto H; Wada J; Kumagai I; Makino H
    Nephron Clin Pract; 2004; 98(3):c93-100. PubMed ID: 15528944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism: a randomized, crossover trial.
    Ito H; Ogata H; Yamamoto M; Takahashi K; Shishido K; Takahashi J; Taguchi S; Kinugasa E
    Clin Nephrol; 2009 Jun; 71(6):660-8. PubMed ID: 19473635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
    Lee SH; Huang TS; Hsieh SJ
    Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between intact PTH and biointact PTH (1-84) with bone and mineral metabolism in pre-dialysis chronic kidney disease (CKD).
    O'Flaherty D; Sankaralingam A; Scully P; Manghat P; Goldsmith D; Hampson G
    Clin Biochem; 2013 Oct; 46(15):1405-9. PubMed ID: 23830844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy of intravenous maxacalcitol and percutaneous ethanol injection therapy lowers serum parathyroid hormone level and calcium x phosphorus product in secondary hyperparathyroidism.
    Tanaka M; Itoh K; Matsushita K; Matsushita K; Fukagawa M
    Nephron Clin Pract; 2006; 102(1):c1-7. PubMed ID: 16166800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of calcitriol on type 5b tartrate-resistant acid phosphatase and interleukin-6 in secondary hyperparathyroidism.
    Lu KC; Tseng CF; Wu CC; Yeung LK; Chen JS; Chao TY; Janckila AJ; Yam LT; Chu P
    Blood Purif; 2006; 24(5-6):423-30. PubMed ID: 16888370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulse oral versus pulse intraperitoneal calcitriol: a comparison of efficacy in the treatment of hyperparathyroidism and renal osteodystrophy in peritoneal dialysis patients.
    Gadallah MF; Arora N; Torres C; Ramdeen G; Schaeffer-Pautz A; Moles K
    Adv Perit Dial; 2000; 16():303-7. PubMed ID: 11045316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
    Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
    Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
    Avbersek-Luznik I; Balon BP; Rus I; Marc J
    Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of PTH fragments for assessment of renal bone disease in hemodialysis patients.
    Fehr T; Garzoni D; Staub T; Binet I; Wüthrich RP
    Kidney Blood Press Res; 2006; 29(3):175-81. PubMed ID: 16931896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
    Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
    Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marked improvement in parameters of renal osteodystrophy with the use of intraperitoneal calcitriol.
    Arora N; Sandroni S; Moles K
    Adv Perit Dial; 1992; 8():62-4. PubMed ID: 1361854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the efficacy of an oral calcitriol pulse or intravenous 22-oxacalcitriol therapies in chronic hemodialysis patients.
    Tamura S; Ueki K; Mashimo K; Tsukada Y; Naitoh M; Abe Y; Kawai H; Tsuchida A; Wakamatsu R; Nojima Y
    Clin Exp Nephrol; 2005 Sep; 9(3):238-43. PubMed ID: 16189633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mineral-bone metabolism markers in young hemodialysis patients.
    Osorio A; Ortega E; Torres JM; Sanchez P; Ruiz-Requena E
    Clin Biochem; 2011 Dec; 44(17-18):1425-8. PubMed ID: 21933667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Acute response of serum PTH and bone markers after injection of 1alpha,25 (OH)2D3 and 22-oxacalcitrol in hemodialysis patient].
    Shimizu G; Mitani S; Matsumoto S; Kawakami A; Nozaki K; Naka H; Imanishi Y; Miki T; Inaba M; Nishizawa Y
    Clin Calcium; 2005 Sep; 15 Suppl 1():148-51; discussion 151. PubMed ID: 16272648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients.
    Liou HH; Chiang SS; Tsai SC; Chang CC; Wu SC; Shieh SD; Huang TP
    Zhonghua Yi Xue Za Zhi (Taipei); 1994 Jun; 53(6):319-24. PubMed ID: 8087705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum cross-linked N-terminal telopeptide of type I collagen for evaluation of renal osteodystrophy in hemodialysis patients.
    Nakashima A; Yorioka N; Mizutani T; Yamagata Z; Ueno T; Takasugi N
    Nephron Clin Pract; 2005; 99(3):c78-85. PubMed ID: 15665550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of parathyroid function in patients with a short history of hemodialysis.
    Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
    Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-calcium dialysate improves mineral metabolism in hemodialysis patients.
    Fujimori A; Yorifuji M; Sakai M; Oyama M; Nakao N; Tokuyama M; Fukagawa M
    Clin Nephrol; 2007 Jan; 67(1):20-4. PubMed ID: 17269595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.